Bruker Corporation (BMV:BRKR)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	927.30M	938.50M	777.70M
United States Revenue Growth	-1.19%	20.68%	11.72%
Germany Revenue	277.60M	310.70M	281.50M
Germany Revenue Growth	-10.65%	10.37%	13.78%
Rest of Europe Revenue	965.70M	873.00M	699.70M
Rest of Europe Revenue Growth	10.62%	24.77%	18.21%
China Revenue	451.50M	471.20M	528.10M
China Revenue Growth	-4.18%	-10.77%	33.19%
Rest of Asia Pacific Revenue	553.70M	518.50M	460.90M
Rest of Asia Pacific Revenue Growth	6.79%	12.50%	12.86%
Total Asia Pacific Revenue	1.01B	989.70M	989.00M
Total Asia Pacific Revenue Growth	1.57%	0.07%	22.87%
Other Countries Revenue	263.10M	254.50M	216.60M
Other Countries Revenue Growth	3.38%	17.50%	13.76%
Revenue (Total)	3.44B	3.37B	2.96B
Revenue (Total) Growth	2.15%	13.56%	17.14%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
BSI BioSpin Revenue	884.20M	905.70M	798.50M
BSI BioSpin Revenue Growth	-2.37%	13.43%	14.61%
BSI CALID Revenue	1.20B	1.09B	960.40M
BSI CALID Revenue Growth	9.67%	13.86%	16.81%
BSI Life Science Revenue	2.08B	2.00B	1.76B
BSI Life Science Revenue Growth	4.21%	13.66%	15.80%
BSI Nano Revenue	1.09B	1.10B	941.90M
BSI Nano Revenue Growth	-0.44%	16.61%	19.68%
Total BSI Revenue	3.18B	3.10B	2.70B
Total BSI Revenue Growth	2.56%	14.69%	17.13%
BEST Revenue	271.50M	283.00M	280.70M
BEST Revenue Growth	-4.06%	0.82%	18.39%
Eliminations from Revenue	-9.50M	-14.10M	-17.00M
Revenue (Total)	3.44B	3.37B	2.96B
Revenue (Total) Growth	2.15%	13.56%	17.14%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
BSI BioSpin Operating Income	90.70M	157.80M	195.90M
BSI BioSpin Operating Income Growth	-42.52%	-19.45%	17.23%
BSI CALID Operating Income	180.20M	180.00M	209.30M
BSI CALID Operating Income Growth	0.11%	-14.00%	6.79%
BSI Life Science Operating Income	270.90M	337.80M	405.20M
BSI Life Science Operating Income Growth	-19.80%	-16.63%	11.59%
BSI Nano Operating Income	-100.10M	2.30M	109.10M
BSI Nano Operating Income Growth	-	-97.89%	-3.45%
Corporate, Eliminations and Other Operating Income	-134.10M	-121.90M	-109.70M
Total BSI Operating Income	36.65M	218.20M	404.60M
Total BSI Operating Income Growth	-83.20%	-46.07%	0.80%
BEST Operating Income	27.30M	34.90M	32.30M
BEST Operating Income Growth	-21.78%	8.05%	3.19%
Operating Income (Other)	-36.65M	-218.20M	-404.60M
Operating Income (Total)	64.00M	253.10M	436.90M
Operating Income (Total) Growth	-74.71%	-42.07%	0.97%

Capital Expenditures

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
BSI BioSpin Capital Expenditures	22.80M	23.90M
BSI BioSpin Capital Expenditures Growth	-4.60%	64.83%
BSI CALID Capital Expenditures	34.10M	31.40M
BSI CALID Capital Expenditures Growth	8.60%	-7.38%
BSI Life Science Capital Expenditures	56.90M	55.30M
BSI Life Science Capital Expenditures Growth	2.89%	14.26%
BSI Nano Capital Expenditures	19.30M	13.90M
BSI Nano Capital Expenditures Growth	38.85%	-31.19%
Corporate Capital Expenditures	14.80M	10.20M
Corporate Capital Expenditures Growth	45.10%	12.09%
Total BSI Capital Expenditures	91.00M	79.40M
Total BSI Capital Expenditures Growth	14.61%	2.19%
BEST Capital Expenditures	24.30M	27.50M
BEST Capital Expenditures Growth	-11.64%	-46.60%

Updated Sep 30, 2025. Data Source: Fiscal.ai.